Heart Failure with Supra-normal Left Ventricular Ejection Fraction – State of the Art

Ziyin Huang,1* Yufeng Jiang,1 Yafeng Zhou1,2
First Affiliated Hospital of Soochow University,1 Jiangsu Province – China
Dushu Lake Hospital Affiliated to Soochow University,2 Jiangsu Province – China
* The authors also contributed to this article.

Abstract
In 2019, an article published in the European Heart Journal recognized for the first time heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 65% as a new HF phenotype, heart failure with supra-normal left ventricular ejection fraction (HFsnEF), with the main purpose of promoting research on this new category. They analyzed mortality in people with HF and found that there was a U-shaped relationship between mortality and LVEF. HFsnEF patients had a higher all-cause mortality compared with other patients diagnosed with HF with preserved ejection fraction (HFP EF). This article describes the current situation of HFsnEF and discusses future perspectives based on the preliminary results of our group. To better treat patients with HFsnEF, it is fundamental that cardiologists and physicians understand the differences and similarities of this new phenotype.

Introduction
It is estimated that more than 100 million people suffer from heart failure (HF) worldwide.1 In the DIGITALIS trial performed in Brazil, 64.2% of these patients were diagnosed with HF with preserved ejection fraction (HFpEF). Recently, a new type of HF, called HF with mid-range ejection fraction (HFmrEF) has been described. According to unpublished data from the DIGITALIS database, the prevalence of HF with reduced ejection fraction (HFrEF) was 19%, HFmrEF was 22% and HFpEF was 59%. It shows that HFpEF accounts for a large proportion of HF.2–4

In an article published in the European Heart Journal, which investigated the relationship between clinically assessed left ventricular ejection fraction (LVEF) and mortality in a large clinical cohort, a U-shaped relationship between mortality and LVEF was found, suggesting that it may be inappropriate to pool all patients with HFmrEF into a single group.5 These results may herald the recognition of a new phenotype of HF with LVEF ≥ 65%, which is characterized by a higher all-cause mortality.6

Heart failure with supra-normal ejection fraction (HFsnEF) has shown to have special clinical manifestations, treatment and prognosis. More research needs to be carried out to explore the characteristics and treatment of this new HF category. The HFsnEF phenotype might be recognized as a clinically relevant classification by national and international guidelines.

Pathophysiology and Pathology of HFsnEF
Optimal left ventricular (LV) performance depends on two conditions: a compliant LV, which allows it to fill from low left atrial pressure during diastole and a firm LV in systole, which ejects the stroke volume at arterial pressure. The echocardiogram is the most commonly used imaging technique to evaluate diastolic and systolic function, and the LVEF is the most widely used index. Patients diagnosed with HFpEF often have a normal LVEF (LVEF ≥ 50%) and that is characterized by diastolic dysfunction.

As a special type of HFpEF, HFsnEF is also characterized by diastolic dysfunction. In a recently published study, it was concluded that patients with higher LVEF have a poorer prognosis.5 The possible reason is that people with hypertrophic hearts (and very high LVEF) may pump more volume of blood with each beat and be particularly susceptible to oxygen supply–mediated ischemia.7 Neurohormonal activation may be another reason for poor prognosis in HFsnEF. Higher LVEF may be due to higher activation of the adrenergic and renin–angiotensin–aldosterone system (RAAS) and higher activation of these systems may contribute to progressive heart remodeling and contractile dysfunction.8 Patients with a remodeled heart were more likely to suffer from cardiac arrest or ventricular fibrillation, when compared with the normal EF group.9 The reasons described above might explain the increased mortality of the HFsnEF patients (Figure 1).

Diagnostic approach
According to the latest ESC Guidelines for acute and chronic HF, the diagnosis of HF is based on the combination of symptoms, signs, natriuretic peptides and results of the echocardiogram.3 In a recent analysis of a large dataset, researchers started defining patients with LVEF ≥ 65% as a new type of HF, called HFsnEF. As a special type of diastolic HF, the diagnosis of HFsnEF may require the presence of signs or symptoms of HF, elevated BNP levels, evidence of normal systolic LV function and evidence of diastolic dysfunction or surrogate markers that include LV hypertrophy.
HFsnEF mechanisms. HFsnEF: heart failure with supra-normal left ventricular ejection fraction; LVEF: left ventricular ejection fraction; RAAS: Renin-angiotensin-aldosterone system.

Table 1 – Clinical criteria in the investigation of HFsnEF

<table>
<thead>
<tr>
<th>Categories</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms and/or signs of HF</td>
<td>Breathlessness, Paroxysmal nocturnal dyspnea, Reduced exercise tolerance, Tiredness, Increased time to recover after exercise, Ankle swelling</td>
</tr>
<tr>
<td></td>
<td>Elevated jugular venous pressure, Hepatojugular reflux, Third heart sound (gallop rhythm), Laterally displaced apical impulse</td>
</tr>
<tr>
<td>LVEF</td>
<td>LVEF ≥65%</td>
</tr>
<tr>
<td>Elevated levels of NPs</td>
<td>BNP&gt;35 pg/mL and/or NT-proBNP&gt;125 pg/mL</td>
</tr>
<tr>
<td>Objective evidence of other cardiac functional and structural alterations underlying HF</td>
<td>Left atrial volume index (LAVI), left ventricular mass index (LVMI), E/e', mean e' septal and lateral wall, longitudinal strain or tricuspid regurgitation velocity (TRV)</td>
</tr>
<tr>
<td>A stress test or invasively measured elevated LV filling pressure</td>
<td>A diastolic stress test performed with echocardiography, Pulmonary capillary wedge pressure (PCWP), Left ventricular end diastolic pressure (LVEDP)</td>
</tr>
</tbody>
</table>

HF: heart failure; LVEF: left ventricular ejection fraction.
LA enlargement, and atrial fibrillation. At the same time, LVEF ≥65% measured by the echocardiogram is one of the essential conditions for the diagnosis of HFnEF. The detailed clinical criteria for the diagnosis of HFnEF are shown in table 1.

### Treatment of HFnEF

Although there is already a rudimentary classification of HF used for precision treatment in HF, a true Precision Medicine approach to HF is currently still in its infancy, and the treatment of HFrEF and HFrEF patients is also based on a “one-size-fits-all” approach.

Based on the pathology and pathophysiology of HFnEF, one can deduce that patients with HFnEF may be sensitive to several traditional drugs that are beneficial for other kinds of HF. But no drugs have shown any experimentally confirmed benefits. For example, β-blockers may be useful for the treatment of HFnEF, as its negative chronotropic effect (decreased heart rate) increases the diastolic filling period and oxygen supply to the myocardium. ACEIs, ARBs and spironolactone may also have an effect on HFnEF by decreasing progressive remodeling. But all of the drugs need prospective studies and clinical trials to identify their effects.

Exercise training in patients with HFnEF may benefit patients by improving exercise tolerance and managing obesity. But the right amount of exercise for HFnEF requires clinical trials to confirm it. In a recently published article, researchers assessed the topic of Precision Medicine in HFrEF. Precision Medicine provides a new concept for the treatment of HF and it may also have an effect on HFnEF.

### Future perspectives

Our recent study has calculated the adjusted hazard ratios (HRs) for mortality with a nadir at LVEF of 60–64% and found that LVEF deviation from 60% to 64% was associated with poorer survival (Figure 2). HFnEF patients had a risk of death that was almost 2-times higher than that of patients with LVEF between 60%-64%. We also divided HFnEF patients into two groups by treating them with ACEIs/ARBs or not. Preliminary data showed a favorable effect on patient survival. ACEIs/ARBs may be attractive therapeutic agents to treat patients with HFnEF. More prospective studies and randomized clinical trials are essential for the establishment of therapies with solid evidence-based recommendations.

After this new HF category has been proposed, there will be increasingly more research on this type of HF, contributing to a better understanding of this new phenotype, and whether an increase in mortality for LVEF ≥65% applies to people with hypertension and obesity remains a significant question that deserves further studies.

### Conclusions

Based on the existing research, we conclude that patients diagnosed with HFnEF (LVEF≥65%) have a special clinical manifestation, which is characterized by a higher all-cause mortality compared with other HFrEF patients.

### Author contributions

Conception and design of the research: Huang Z, Zhou Y; Data acquisition, Analysis and interpretation of the data, Statistical analysis and Writing of the manuscript: Huang Z, Jiang Y; Obtaining financing: Zhou Y; Critical revision of the manuscript for intellectual content: Jiang Y, Zhou Y.

---

Figure 2 – Adjusted Hazard Ratio for mortality according to LVEF.
Potential Conflict of Interest
The authors report no conflict of interest concerning the materials and methods used in this study or the findings specified in this paper.

Sources of Funding
This study was funded by National Natural Science Foundation of China (81873484) and Natural Scientific Foundation of Jiangsu Province (BK20161226).

References

This study was partially funded by Jiangsu Province’s Key Provincial Talents Program (ZDRCA2016043) and Jiangsu Province’s 333 High-Level Talents Project (BRA2017539).

Study Association
This study is not associated with any thesis or dissertation.

Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.